Perspective Therapeutics, Inc.

Revenue for the fiscal first quarter ended September 30, 2022 was $1.72 million, down from $2.56 million in the prior-year quarter. Gross profit was $414,000, and gross margin was 24.1% versus 40.1% a year ago. Net loss was $4.07 million, or $0.03 per diluted share, versus a net loss of $2.4 million, or $0.02 per share, in the prior-year quarter. Operating expenses were $4.6 million versus $3.3 million last year, with G&A up 69% to $3.1 million. Cash, cash equivalents and short-term investments were $54.1 million at quarter end, versus $55.9 million at June 30, 2022, and the company had zero long-term debt. Management did not provide formal next-quarter or full-year financial guidance on the call.

Lori Woods framed the merger with Viewpoint as a transformational pivot that extends Isoray beyond its brachytherapy roots into targeted radiopharmaceuticals and imaging. She said the company had done a rigorous market review and believes the combined platform can support future product development and shareholder value over time. Her tone was upbeat and strategic, with emphasis on long-term clinical milestones rather than near-term financial results.

Jonathan Hunt said the quarter was pressured by the isotope supply disruption, which reduced revenue and gross margin and left sales below what the company would have expected based on recent quarters. He tied higher operating expenses mainly to merger-related legal, due diligence, and investment banking costs, while also noting payroll, bonuses, insurance, audit and travel increases. He reported $54.1 million in cash, cash equivalents and short-term investments, approximately $0.38 per share, and zero long-term debt, underscoring a strong balance sheet despite the quarterly loss.

Analysts asked how much of the quarter’s revenue shortfall was due to the isotope disruption and whether there would be more impact in Q2; management said the hit was significant but did not quantify it, and said supply has now recovered. Questions also focused on what Viewpoint expects to disclose in 2023; Thijs Spoor said the company expects full results from the Mayo imaging-only melanoma study and will begin sharing open-label therapeutic updates as patients are imaged and treated. Analysts probed merger synergies and whether brachytherapy and alpha therapy compete; management said the businesses are complementary, with shared functions, physician relationships and a patient-specific treatment model rather than direct competition.